The First and Only USDA Conditionally Approved Treatment for Parvo
The First and Only USDA Conditionally Approved Treatment for Parvo
Canine Parvovirus Monoclonal Antibody (CPMA), CPMA is a single intravenous injection that neutralizes the parvo virus. CPMA helps provide quicker recovery for dogs and a better treatment experience for shelters.
9/10 satisfaction rating1
83% of current users recommend to other vets1
Less doctor and staff time needed when incorporated into protocols1
Targeted Efficacy
After challenged with virulent CPV-2b, zero dogs died when treated with Canine Parvovirus Monoclonal Antibody.3
Why choose Canine Parvovirus Monoclonal Antibody?
We anticipate Canine Parvovirus Monoclonal Antibody will help greatly decrease the burden of supportive care for CPV. You may be able to save days of labor and stress associated with managing the symptoms of this potentially deadly disease.
mAb that targets parvovirus directly
Single-dose efficacy
High safety profile
May help decrease burden of supportive care and may help reduce emotional stress
Check Out These CPMA Resources for Shelters
Abstract: CPMA Efficacy in a shelter parvo ICU
VetGirl CPMA Podcast
In this VETgirl podcast, we talk to shelter veterinarian, Dr. Brian DiGangi, MS, DABVP (Canine & Feline Practice, Shelter Medicine Practice), on what you need to know about parvovirus outbreaks in shelters.
Parvo FAQs – Learn More About Parvo and CPMA
Order Now
For Immediate Orders: Call 1-800-782-8977
(Select option 2 and then option 2 again) OR
Email: elancovet@elancoah.com
Paws4Purpose
Participating in the Paws 4 Purpose program is an easy way to help your organization reach and maintain the high standards of disease prevention, diagnosis and treatment outlined in the Five Freedoms for Animal Welfare. You’ll also receive expert support, training resources, access to continuing education content and trusted quality products, including CPMA.
To learn more contact your Elanco Sales Representative.
Always read, understand and follow the label and use directions.
